Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Evaluation of Reversine as an anticancer drug in oral cancer Speaker: Wei-Ching Wu Advisor: Dr. Hau-Ren Chen Date: 6/04/2010 Betal quid-chewing induced oral cancer is a common disease in South Asia. The incidence of oral cancer is about 11% of male population in Taiwan, and the mortality of oral cancer is about 8%. Surgery and radiation are the effective therapies in oral cancer treatment. In addition, the chemotherapy agents such as 5-Fu and Cisplatin are used in oral cancer commonly. However, the five-year survival rate is less than 30% even though the treatments. Therefore, it is imperative to investigate the novel and the effective drugs in oral cancer treatment. Reversine is a synthetic purine-like small molecular which is first identified as a de-differentiation agent in murine myoblast cell lines. Moreover, it has been demonstrated as an inhibitor of Aurora kinase and which can prohibit the survival of leukemia cells. Because Aurora kinase has also been reported to overexpress and contribute to the oral cancer tumorigenesis. In this study, we propose that Reversine may be a novel anticancer agent in oral cancer. To verify this hypothesis, two oral squamous cell carcinoma (OSCC) cell lines, OC2 and OCSL, were used to test the influence of Reversine in cellular variability. Cell counting after Reversine treatment showed that the IC50 is about 5uM in 24 hours. Moreover, cell cycle analysis and western blot showed that Reversine might induce cell cycle arrest in G2/M phase. In addition, apoptosis was also be detected by flow cytometry during Reversine treatment. Western blot analysis was further used to elucidate that Reversine could induced caspase-dependent cell death in oral cancer cell lines. Taken together, our results suggested that Reversine can be a novel anticancer agent in oral cancer therapy. Evaluation of Reversine as an anticancer drug in oral cancer Date: 6/4/2010 Code: Comment: Speaker: Wei-Ching Wu Score: Adviser: Dr. Hau-Ren Chan